Warner Bros. late June 10 issued a statement pertaining to comments “Harry Potter” author J.K. Rowling made last weekend about transgender identity. In a series of posts on social media, Rowling said women should be identified by their biological sex rather than gender identity.
“If sex isn’t real, there’s no same-sex attraction,” Rowling wrote on her website. “If sex isn’t real, the lived reality of women globally is erased. I know and love trans people, but erasing the concept of sex removes the ability of many to meaningfully discuss their lives. It isn’t hate to speak the truth.”
Rowling’s comments produced pushback on social media from the LGBTQ community and supporters claiming the author was advocating against her own message of inclusivity and empathy found in many “Harry Potter” books.
“Potter” stars Emma Watson and Daniel Radcliffe, in addition to “Fantastic Beasts” star Eddie Redmayne took to social media in support of the transgender community.
“Transgender women are women,” Radcliffe wrote on a post. “Any statement to the contrary erases the identity and dignity of transgender people and goes against all advice given by professional health care associations who have far more expertise on this subject matter …”
Warner said the events in the past several weeks affirmed its resolve as a company to confront difficult societal issues — including fostering a diverse and inclusive culture.
“We deeply value the work of our storytellers who give so much of themselves in sharing their creations with us all,” the studio said in a statement. “We recognize our responsibility to foster empathy and advocate understanding of all communities and all people, particularly those we work with and those we reach through our content.”
For Warner, the controversy comes as Rowling is writing the script for Fantastic Beasts 3 and other projects near and dear to the studio’s bottom line. The “Potter” movie franchise has resulted in more than $6.5 billion at the global box office, in addition to millions more in home entertainment sales.